Comparative Study between Primary Percutaneous Coronary Intervention With and Without the Infusion of Eptifibatide Efficacy and Safety
/ 0
- Details
- Category: Vol. 80, December 2012
- Hits: 645
Comparative Study between Primary Percutaneous Coronary Intervention With and Without the Infusion of Eptifibatide Efficacy and Safety,SAID ABD EL-KREEM, KHALED A. FOUAD and SAMEH THABET
Abstract
Introduction: Primary percutaneous coronary intervention (PCI) is the most effective available method to restore coronary perfusion in acute STEMI, where normal coronary flow can be restored in 85% of patients. Several randomized clinical trials have shown that inhibition of platelet aggregation with platelet GP IIb/IIIa inhibitors improves outcome in patients undergoing primary PCI.
Aim of the Work: To assess the benefit and the short term-outcome of the use of Eptifibatide I.V Infusion in primary percutaneous coronary intervention.
Patients and Methods: 40 consecutive patients with acute ST segment elevation myocardial infarction (STEMI) present-ing within 12 hours of chest pain eligible for primary PCI. Divided into two groups: group A: 20 patients were managed by upstream Eptifibatide, group B: 20 patients were managed by primary PCI without the use of Eptifibatide infusion, short term MACE were determined in both group.
Results: The baseline demographic and clinical data were similar in both group, Death occurred in 0% in group A and 10.5% in group B (p-value 0.220). Reinfarction occurred in 0% in group A and 11.8% in group B (p-value 0.19). TVR occurred in 0% of patients in group A and 5.9% in group B (0.45). Stroke occurred in 0% of patients in group A and 5.9% in group B (p-value 0.45). Stent thrombosis occurred in 0% of patients in group A and 17.6% in group B (p-value 0.08). Total MACE in group A is 0% and 0.473% in group B. (p-value 0.003).
No cases of minor or major bleeding occurred in patients in group A. Only 3 cases of minor bleeding occurred in patients in group B in the form of vascular access site hematoma with no cases of major bleeding.
Conclusion: The use of glycoprotein inhibitors Eptifibatide in primary PCI improves short term clinical outcome and reduces periprocedural ischemic complications without in-crease in bleeding.